Cargando…

Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials

BACKGROUND: Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in children...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Xue, Liu, Xue-han, Lu, Chun-li, Jin, Xin-yan, Liu, Qiang, Wang, Xiao-qin, Liu, Jian-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573979/
https://www.ncbi.nlm.nih.gov/pubmed/34743723
http://dx.doi.org/10.1186/s12906-021-03415-x
_version_ 1784595527805960192
author Xue, Xue
Liu, Xue-han
Lu, Chun-li
Jin, Xin-yan
Liu, Qiang
Wang, Xiao-qin
Liu, Jian-ping
author_facet Xue, Xue
Liu, Xue-han
Lu, Chun-li
Jin, Xin-yan
Liu, Qiang
Wang, Xiao-qin
Liu, Jian-ping
author_sort Xue, Xue
collection PubMed
description BACKGROUND: Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in children with HSPN. This study aimed to evaluate the effectiveness and safety of HQH for HSPN in children, so as to provide evidence for clinical use. METHODS: Randomized controlled trials (RCTs) on HQH for HSPN in children were searched in eight Chinese and English databases from their inception to December 2020. We included children with HSPN received HQH combined with conventional medicine. Cochrane “Risk of bias” tool was used to assess methodological quality, and “Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach” to summarize the certainty of evidence for main findings. Effect estimates were presented as risk ratio (RR), mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) in meta-analyses using RevMan 5.3. Data not suitable for statistical pooling were synthesized qualitatively. RESULTS: In total seven RCTs were identified. Compared with conventional medicine alone, HQH plus conventional medicine showed the better effect in improving clinical cure rate (RR 1.58; 95%CI 1.17 to 2.14; n = 6) and total effective rate (RR 1.34; 1.16 to 1.54; n = 6); reducing urine sediment erythrocyte count (MD -9.23; − 10.76 to − 7.69; n = 3) and urine β2 micro-globulin level (MD -0.09; − 0.12 to − 0.06; n = 2). No serious adverse event was recorded in all included trials. CONCLUSIONS: Limited evidence showed HQH combined with conventional medicine had a beneficial effect for children with HSPN, and the side effects were mild. HQH may be a promising complementary therapy. However, long term follow-up, high quality and multicenter RCTs are required to confirm the findings.
format Online
Article
Text
id pubmed-8573979
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85739792021-11-08 Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials Xue, Xue Liu, Xue-han Lu, Chun-li Jin, Xin-yan Liu, Qiang Wang, Xiao-qin Liu, Jian-ping BMC Complement Med Ther Research Article BACKGROUND: Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in children with HSPN. This study aimed to evaluate the effectiveness and safety of HQH for HSPN in children, so as to provide evidence for clinical use. METHODS: Randomized controlled trials (RCTs) on HQH for HSPN in children were searched in eight Chinese and English databases from their inception to December 2020. We included children with HSPN received HQH combined with conventional medicine. Cochrane “Risk of bias” tool was used to assess methodological quality, and “Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach” to summarize the certainty of evidence for main findings. Effect estimates were presented as risk ratio (RR), mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) in meta-analyses using RevMan 5.3. Data not suitable for statistical pooling were synthesized qualitatively. RESULTS: In total seven RCTs were identified. Compared with conventional medicine alone, HQH plus conventional medicine showed the better effect in improving clinical cure rate (RR 1.58; 95%CI 1.17 to 2.14; n = 6) and total effective rate (RR 1.34; 1.16 to 1.54; n = 6); reducing urine sediment erythrocyte count (MD -9.23; − 10.76 to − 7.69; n = 3) and urine β2 micro-globulin level (MD -0.09; − 0.12 to − 0.06; n = 2). No serious adverse event was recorded in all included trials. CONCLUSIONS: Limited evidence showed HQH combined with conventional medicine had a beneficial effect for children with HSPN, and the side effects were mild. HQH may be a promising complementary therapy. However, long term follow-up, high quality and multicenter RCTs are required to confirm the findings. BioMed Central 2021-11-08 /pmc/articles/PMC8573979/ /pubmed/34743723 http://dx.doi.org/10.1186/s12906-021-03415-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Xue, Xue
Liu, Xue-han
Lu, Chun-li
Jin, Xin-yan
Liu, Qiang
Wang, Xiao-qin
Liu, Jian-ping
Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_full Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_fullStr Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_full_unstemmed Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_short Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_sort chinese patent herbal medicine huaiqihuang for henoch-schonlein purpura nephritis in children: a systematic review of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573979/
https://www.ncbi.nlm.nih.gov/pubmed/34743723
http://dx.doi.org/10.1186/s12906-021-03415-x
work_keys_str_mv AT xuexue chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
AT liuxuehan chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
AT luchunli chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
AT jinxinyan chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
AT liuqiang chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
AT wangxiaoqin chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
AT liujianping chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials